Gynaecology Cervical
Bevacizumab 15mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy
Indication
00716a
Bevacizumab in combination with CARBOplatin and PACLitaxel for the treatment of persistent recurrent or metastatic cervical cancer, not amenable to curative surgery or radiation therapy
Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy
Indication
00799a
Locally advanced metastatic or recurrent or metastatic cervical cancer, not amenable to curative surgery or radiation therapy
CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)
Indication
00419b
Chemoradiation treatment in locally advanced cervical cancer when CISplatin is contraindicated or not tolerated
CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy
Cemiplimab Therapy
Indication
00812a
As monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy
CISplatin (40mg/m2) Weekly with Radiotherapy (RT)
Indication
00385a
Definitive chemoradiation treatment for locally advanced (stage IIB to IVA*) cervical squamous cell carcinoma (SCC), adeno-squamous cell carcinoma and adenocarcinoma of the cervix
00385e
Post-operative adjuvant chemoradiation treatment for squamous cell carcinoma, adeno-squamous cell carcinoma and adenocarcinoma of the cervix with unexpected pathological node positivity
CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day
Pembrolizumab 200mg Monotherapy
Indication
00455j
For the maintenance treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS ≥ 1 who have completed the induction chemotherapy component of the treatment
Pembrolizumab 400mg Monotherapy
Indication
00558j
For the maintenance treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS ≥ 1 who have completed the induction chemotherapy component of the treatment
Pembrolizumab, PACLitaxel 175mg/m2 , CARBOplatin AUC 5 and Bevacizumab Therapy
Indication
00811a
Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥ 1
Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy
Indication
00817a
Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥ 1
Pembrolizumab in combination with chemoradiotherapy
Indication
00943
Pembrolizumab in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy
Gynaecology Endometrial
CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy
CISplatin (50mg/m2 ) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2 ) - Endometrial Cancer
Indication
00676a
Adjuvant treatment for high risk, stage I (grade 3 with deep myometrial invasion and/or lymph-vascular invasion) stage II or III endometrial carcinoma or stage I - III endometrial carcinoma with serous or clear cell histology following surgery
Dostarlimab Therapy
Indication
00819a
As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
Dostarlimab, PACLitaxel and CARBOplatin Therapy
Indication
00929a
The treatment of adults with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy
Pegylated Liposomal DOXOrubicin 50mg/m2 28 days Regimen
Gestational Trophoblastic Neoplasia (GTN)
DACTINomycin Therapy
Indication
00247a
Alternative treatment of low risk gestational trophoblastic disease (GTD) (risk score ≤ 6)
EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, cycloPHOSphamide, vinCRIStine)
Indication
00248a
Treatment of high risk gestational trophoblastic neoplasia (GTN) (FIGO score ≥7).
00248b
Treatment of patients with low risk GTN who have not responded or have relapsed from single agent chemotherapy (methotrexate or actinomycin D).
EMA/EP Therapy (Etoposide Methotrexate DACTINomycin/Etoposide CISplatin)
Indication
00264a
Treatment of women with high-risk Gestational Trophoblastic Neoplasia (GTN) who have not responded or have relapsed from treatment with EMA/CO.
00264b
GTN and hepatic metastases. Women with GTN and hepatic metastases at presentation.
Intrathecal Methotrexate for CNS prophylaxis in GTN
Indication
00249a
Central nervous system (CNS) prophylaxis in patients with high risk gestational trophoblastic neoplasia (GTN).
00249b
Central nervous system (CNS) prophylaxis in patients with low risk gestational trophoblastic neoplasia (GTN) with lung metastases.
Methotrexate 8 day Charing Cross Regimen
Indication
00246a
Treatment of low risk gestational trophoblastic disease (GTD) (FIGO score ≤ 6).
PACLitaxel/Etoposide alternating with PACLitaxel/CISplatin (TE/TP) Therapy
Indication
00266a
Treatment of women with high-risk Gestational Trophoblastic Neoplasia (GTN) who have not responded or have relapsed from treatment with EMA/CO.
Two Day Etoposide CISplatin (EP) Therapy
Indication
00267a
Emergency treatment of women with Gestational Trophoblastic Neoplasia (GTN) who are acutely unwell from liver or CNS disease and particularly those at risk of respiratory failure.
00267b
Hepatic Metastases.
Women with GTN who are acutely unwell from liver disease.
00267c
Cerebral Metastases.
Women with GTN who are acutely unwell from cerebral metastases.
Ovarian
Bleomycin, Etoposide and CISplatin (BEP) Therapy
Indication
00300a
Adjuvant treatment of high risk (vascular invasion carcinoma) stage 1 nonseminoma germ cell tumour.
00300b
Metastatic germ cell tumours of the testis.
00300c
Advanced stage or metastatic germ cell tumours (dysgermimoma) of the ovaries.
00300d
Extra-gonadal germ cell tumours.
Bevacizumab 10mg/kg Therapy-14 day
Indication
00212b
In combination with paclitaxel, topotecan (given weekly), or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy
Indication
00766a
For the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer
Bevacizumab 15mg/kg Therapy-21 day
Indication
00215a
In combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
00215c
In combination with, topotecan given on days 1-5 every 3 weeks*, for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
Bevacizumab 10mg/kg and Pegylated liposomal DOXOrubicin 40mg/m2 Therapy
Indication
00772a
For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy
Indication
00620a
Bevacizumab in combination with CARBOplatin and PACLitaxel is indicated as first line post-surgical treatment in FIGO stage III after surgery with residual disease ≥ 1cm or FIGO stage IV:
Epithelial ovarian
Fallopian tube
Primary peritoneal cancer
Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (Day 1, 8, 15 and 22) Therapy
Indication
00769a
For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
Bevacizumab 10mg/kg and Topotecan 4mg/m2 Therapy
Indication
00771a
For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy
Indication
00766a
For the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
CARBOplatin (AUC 4-6) Monotherapy- 21 day
Indication
First line adjuvant therapy of
00261a
ovarian carcinoma of epithelial origin
00261b
primary peritoneal carcinoma
00261c
fallopian tube cancer
where combination therapy is not suitable.
CARBOplatin (AUC 4-6) Monotherapy- 21 day
Indication
First line therapy of advanced Stage 3 and 4
00261d
ovarian carcinoma of epithelial origin
00261e
primary peritoneal carcinoma
00261f
fallopian tube cancer
where surgery is not feasible and where combination therapy is not suitable.
CARBOplatin (AUC 4-6) Monotherapy- 21 day
Indication
Treatment of recurrent, platinum-sensitive,
00261g
invasive ovarian carcinoma of epithelial origin
00261h
primary peritoneal carcinoma
00261i
fallopian tube cancer.
CARBOplatin (AUC 4-6) Monotherapy- 28 day
Indication
First line adjuvant therapy of
00251a
ovarian carcinoma of epithelial origin
00251b
primary peritoneal carcinoma
00251c
fallopian tube cancer
where combination therapy is not suitable.
CARBOplatin (AUC 4-6) Monotherapy- 28 day
Indication
First line therapy of advanced Stage 3 and 4
00251d
ovarian carcinoma of epithelial origin
00251e
primary peritoneal carcinoma
00251f
fallopian tube cancer
where surgery is not feasible and where combination therapy is not suitable.
CARBOplatin (AUC 4-6) Monotherapy- 28 day
Indication
Treatment of recurrent, platinum-sensitive,
00251g
invasive ovarian carcinoma of epithelial origin
00251h
primary peritoneal carcinoma
00251i
fallopian tube cancer
Carboplatin AUC 5, Pegylated Liposomal Doxorubicin 30mg/m2
Indication
00624a
Treatment of patients with platinum sensitive relapsed/recurrent ovarian cancer
00624b
Treatment of patients with platinum sensitive relapsed/recurrent primary peritoneal cancer
00624c
Treatment of patients with platinum sensitive relapsed/recurrent fallopian tube cancer
CARBOplatin (AUC 6) and Weekly PACLitaxel 80mg/m2 Therapy
Indication
00308a
Adjuvant treatment of high risk, stage I, epithelial ovarian cancer*
00308b
Treatment of advanced ovarian cancer*
00308c
Treatment of primary peritoneal cancer*
00308d
Treatment of fallopian tube cancer*
CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy
Indication
00303a
Adjuvant treatment of high risk, stage I, epithelial ovarian cancer*
00303b
Treatment of advanced ovarian cancer
00303c
Treatment of primary peritoneal cancer
00303d
Treatment of fallopian tube cancer
00303g
Treatment of carcinoma of unknown primary site*
DOCEtaxel Monotherapy 75mg/m2 - 21 day cycle
Indication
00203e
Treatment of Relapsed/Progressing primary peritoneal carcinoma
00203f
Treatment of Relapsed/Progressing Epthelial Ovarian carcinoma
00203g
Treatment of Relapsed/Progressing Fallopian Tube carcinoma
Etoposide and CISplatin 20mg/m2 (EP) 5 Day Therapy
Indication
00301a
Treatment of good prognosis (IGCCCG criteria) metastatic germ cell tumours (both non-seminoma and seminoma)
Gemcitabine 1000mg/m2 and CARBOplatin (AUC 4) Therapy-21 day
Indication
00306a
Treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy.
00306b
Treatment of patients with fallopian tube cancer with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy*
00306c
Treatment of patients with primary peritoneal cancer with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy*
Gemcitabine(1000mg/m2),CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy- 21 day
Indication
00499a
Treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents
Intravenous Vinorelbine Therapy-21 days
Niraparib (Tablets) Monotherapy
Indication
00862a
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00862b
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00862c
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00862d
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
00862e
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) fallopian tube cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
00862f
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
Olaparib (Tablet) and Bevacizumab Therapy
Indication
00746a-c
Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (GIS).
Olaparib (Tablet) Monotherapy
Indication
00588a
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high grade epithelial ovarian cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588b
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) fallopian tube cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588c
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) primary peritoneal carcinoma who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588d
Maintenance treatment of adult patients with platinum - sensitive relapsed BRCA-mutated (germline and/or somatic) - high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
00588e
Maintenance treatment of adult patients with platinum - sensitive relapsed BRCA-mutated (germline and/or somatic) fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
00588f
Maintenance treatment of adult patients with platinum - sensitive relapsed BRCA-mutated (germline and/or somatic) primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 - 28 Day
Indication
00226b*
Second-line chemotherapy for metastatic ovarian cancer after failure of standard, platinum-containing therapy.
PACLitaxel 80mg/m2 Day 1, 8, 15 Monotherapy - 28 Day
Indication
00621c*
Second-line chemotherapy for metastatic ovarian cancer after failure of standard, platinum-containing therapy.
Pegylated Liposomal DOXOrubicin 50mg/m2 28 days Regimen
Indication
00205b
Treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.
Rucaparib (Tablets) Monotherapy
Indication
00904a-c
As monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV)
- high-grade epithelial ovarian,
- fallopian tube, or
- primary peritoneal cancer
who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
Topotecan Monotherapy-5 day
Indication
00311a
Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy
00311c
Treatment of patients with metastatic carcinoma of the fallopian tubes after failure of first-line or subsequent therapy*
00311d
Treatment of patients with metastatic peritoneal carcinoma after failure of first-line or subsequent therapy*
Topotecan Monotherapy-Weekly
Indication
00312a
Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy
00312b
Treatment of patients with metastatic carcinoma of the fallopian tubes after failure of first-line or subsequent therapy
00312c
Treatment of patients with metastatic peritoneal carcinoma after failure of first-line or subsequent therapy